Enliven Therapeutics adds Kristine Ball to board ahead of planned Phase 3 CML trial

Enliven Therapeutics announced on October 14, 2026 that it had appointed Kristine Ball to its Board of Directors, effective immediately, ahead of the company's planned initiation of the pivotal Phase 3 trial of relcobatinib before year-end.¹

According to the company's 8-K filing, Enliven's board increased in size from seven to eight directors and named Ball a Class II director with a term expiring at the 2028 annual meeting, also seating her on the Audit Committee, effective October 14, 2026.¹

Ball's background spans both clinical-stage and commercial-stage biopharmaceutical work. The filing states she has served as Chief Executive Officer of Antiva Biosciences, Chief Executive Officer of Soteria Biotherapeutics, and in finance leadership roles at Menlo Therapeutics and Relypsa, including as CFO at Relypsa during its move from clinical development into commercial operations.¹ She also currently sits on the board of Oruka Therapeutics where she chairs the Audit Committee, and has previously served on the boards of Atreca and Forty Seven.¹

On compensation, the filing discloses that Ball will receive $45,000 per year for board service and an additional $10,000 per year for Audit Committee service.¹ She was also granted stock options valued at approximately $650,000 at grant date under U.S. GAAP.¹ The options vest at 1/36th per month over three years, contingent on continued service.¹

On the clinical program, Enliven said it is moving toward starting the Phase 3 "ENABLE-2" trial of relcobatinib (ELVN-001) for patients previously treated for chronic myeloid leukemia, citing recent FDA alignment on the final trial design, with initiation still targeted before year-end 2026.¹